絞り込み

16644

広告

欧州初、フランスで新型肺炎感染確認 パリとボルドーで計2人 (毎日新聞)

[PR] フランスのビュザン保健相は24日、パリと南西部ボルドーで、中国・武漢を中心に新型肺炎を引き起こしているコロナウイルス感染者計2人を確認したと発表した。...

  1. [医学] 常に肌を触れ合わせた母親と早産...
  2. 新型肺炎 湖北省で新たに15人死亡 中国...
  3. [医学] 肝臓線維症の解消にPPARγや...
  4. 新型肺炎 “初期症状 発熱・せきとは限ら...

ニュース一覧

A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.

著者 Vachon CM , Schaid DJ , Ingle JN , Wickerham DL , Kubo M , Mushiroda T , Goetz MP , Carlson EE , Paik S , Wolmark N , Nakamura Y , Wang L , Weinshilboum R , Couch FJ
Breast Cancer Res Treat.2015 Jan 10 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (9,547view , 2users)

Full Text Sources

Medical

Miscellaneous

Molecular Biology Databases

Recent genetic studies have identified common variation in susceptibility loci that stratify lifetime risks of breast cancer and may inform prevention and screening strategies. However, whether these loci have similar implications for women treated with tamoxifen or raloxifene (SERMs) is unknown. We conducted a matched case-control study of 592 cases who developed breast cancer and 1,171 unaffected women from 32,859 participants on SERM therapy enrolled on NSABP P-1 and P-2 breast cancer prevention trials. We formed a quantitative polygenic risk score (PRS) using genotypes of 75 breast cancer-associated single nucleotide polymorphisms and examined the PRS as a risk factor for breast cancer among women treated with SERMs. The PRS ranged from 3.98 to 7.74, with a one-unit change associated with a 42 % increase in breast cancer (OR = 1.42; P = 0.0002). The PRS had a stronger association with breast cancer among high-risk women with no first-degree family history (OR = 1.62) compared to those with a positive family history (OR = 1.32) (P intx = 0.04). There was also suggestion that PRS was a stronger risk factor for ER-positive (OR = 1.59, P = 0.0002) than ER-negative (OR = 1.05, P = 0.84) breast cancer (P intx = 0.10). Associations did not differ by tamoxifen or raloxifene treatment, age at trial entry, 5-year predicted Gail model risk or other clinical variables. The PRS is a strong risk factor for ER-positive breast cancer in moderate to high-risk individuals treated with either tamoxifen or raloxifene for cancer prevention. These data suggest that common genetic variation informs risk of breast cancer in women receiving SERMs.
PMID: 25575444 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード